首页 | 本学科首页   官方微博 | 高级检索  
     

银杏叶史话:中药/植物药研究开发的典范
引用本文:杨扬,周斌,赵文杰. 银杏叶史话:中药/植物药研究开发的典范[J]. 中草药, 2016, 47(15): 2579-2591
作者姓名:杨扬  周斌  赵文杰
作者单位:中国医药工业研究总院上海医药工业研究院, 上海 201203;中国医药工业研究总院上海医药工业研究院, 上海 201203;中国医药工业研究总院上海医药工业研究院, 上海 201203
基金项目:国家科技攻关计划项目(2001BA701A07-27)
摘    要:从银杏叶的活性成分、药理作用、毒性与临床应用、各国药典质量标准的比较、药用发展史和我国银杏叶研究开发的现状进行详尽地阐述、分析与讨论。银杏叶的药用历史始于我国宋代,日本、德国的科学家在研究开发方面作出了开创性重要贡献,其发展史充分体现了锐意创新,成为中药/植物药研究开发的典范。我国银杏叶创新药物的研究已取得了长足进展,获得了重大成果,但我国银杏叶提取物及其制剂的质量标准与欧美存在明显差距,产业集中度较低。

关 键 词:银杏叶  中药  植物药  质量标准  创新药物
收稿时间:2016-01-16

Ginkgo biloba leaves history: A model of research and development for Chinese materia medica/phytomedicine
YANG Yang,ZHOU Bin and ZHAO Wen-jie. Ginkgo biloba leaves history: A model of research and development for Chinese materia medica/phytomedicine[J]. Chinese Traditional and Herbal Drugs, 2016, 47(15): 2579-2591
Authors:YANG Yang  ZHOU Bin  ZHAO Wen-jie
Affiliation:Shanghai Institute of Pharmceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 201203, China;Shanghai Institute of Pharmceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 201203, China;Shanghai Institute of Pharmceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 201203, China
Abstract:Summary in this paper, the active chemical constituents from Ginkgo biloba leaves (GBL), their pharmacological effects, toxicity studies, clinical application, the comparison with the quality standard of the Pharmacopoeia, the history of medicinal development as well as the research and development of GBL in China were described, analyzed, and discussed in detail. GBL began to be recorded the medicinal value from the Song Dynasty in China. The scientists in research and development of GBL in Japanese and German have made significant pioneering contributions. The history of medicinal development of GBL has been fully embodied in the innovation, and has become a model for the research and development of Chinese materia medica and phytomedicine. The innovative drug research of GBL in China has made considerable progress, the significant results have been obtained. But the quality standard of Chinese GBL extract and its preparations have a significant difference with the European and American industries. The industry concentration is low.
Keywords:Ginkgo biloba L.  Chinese materia medica  phytomedicine  quality standard  innovative drug
本文献已被 CNKI 等数据库收录!
点击此处可从《中草药》浏览原始摘要信息
点击此处可从《中草药》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号